Welcome to our dedicated page for Diamedica Therapeutics news (Ticker: DMAC), a resource for investors and traders seeking the latest updates and insights on Diamedica Therapeutics stock.
DiaMedica Therapeutics Inc (DMAC) is a clinical-stage biopharmaceutical company advancing novel therapies for neurological disorders and chronic kidney disease. This page serves as the definitive source for DMAC-related news, providing investors and researchers with timely updates on clinical developments, regulatory milestones, and corporate announcements.
Access the latest press releases detailing progress on DM199 – the company's recombinant human tissue kallikrein-1 therapy – along with strategic partnerships and peer-reviewed research findings. Our curated news collection covers essential updates including trial results, FDA communications, and scientific presentations, helping stakeholders track the company's progress in addressing unmet medical needs.
Key focus areas include advancements in acute ischemic stroke treatments and chronic kidney disease management. Bookmark this page for streamlined access to earnings reports, investor conference materials, and analysis of DMAC's position within the competitive biopharmaceutical landscape. All content is maintained to reflect the most current and relevant information for informed decision-making.
DiaMedica Therapeutics Inc. (NASDAQ: DMAC) announced the appointment of David Wambeke as Chief Business Officer (CBO) to spearhead business development initiatives. Mr. Wambeke brings over 15 years of life sciences and investment banking experience, having previously been involved in over 100 financing transactions. He will play a crucial role as the company resumes enrollment in its ReMEDy2 trial for acute ischemic stroke (AIS).
In conjunction with his appointment, Mr. Wambeke purchased
DiaMedica Therapeutics (Nasdaq: DMAC) provided a business update and 2022 financial results, highlighting ongoing communications with the FDA regarding the clinical hold on its ReMEDy2 trial. The company completed Part 1 of an in-use study, with results indicating a proposed dose revision could prevent hypotension issues. As of December 31, 2022, DiaMedica reported cash and investments of $33.5 million, a decline from $45.1 million in 2021, primarily due to operational costs. R&D expenses decreased to $7.8 million, while G&A expenses rose to $6.2 million. Management will discuss these results in a conference call on March 29, 2023.
DiaMedica Therapeutics Inc. (Nasdaq: DMAC) will announce its full-year 2022 financial results after market close on March 28, 2023. A live conference call to discuss the results and provide a business update is scheduled for March 29, 2023, at 7:00 AM Central Time. Interested parties can join the call by dialing (877) 550-1858 or via webcast. DM199, DiaMedica's lead candidate, is a recombinant KLK1 protein aimed at treating acute ischemic stroke. The webcast will be available for playback on the company's website for 12 months post-call.
DiaMedica Therapeutics Inc. (NASDAQ: DMAC), a clinical-stage biopharmaceutical firm, announced that CEO Rick Pauls will present a corporate overview at the Oppenheimer 33rd Annual Healthcare Conference from March 13-15, 2023. Mr. Pauls is scheduled to speak at 2:40 p.m. ET on March 15, and will also be available for one-on-one investor meetings throughout the event. DiaMedica's lead candidate, DM199, is the first synthetic form of the KLK1 protein, aiming to treat acute ischemic stroke and chronic kidney disease. Investors can contact their Oppenheimer representative to arrange meetings.
FAQ
What is the current stock price of Diamedica Therapeutics (DMAC)?
What is the market cap of Diamedica Therapeutics (DMAC)?
